Cadrenal Therapeutics, Inc.
CVKD
$15.50
-$0.775-4.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -265.99% | -132.30% | -138.58% | 67.85% | 79.64% |
| Total Depreciation and Amortization | -33.33% | -33.33% | -16.67% | 200.00% | -33.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | 640.25% | 95.76% | 14.95% | -96.17% | -97.84% |
| Change in Net Operating Assets | 372.10% | -136.76% | 1,609.95% | 32.16% | -15.43% |
| Cash from Operations | -157.88% | -250.62% | -92.28% | -29.98% | -73.73% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -76.52% | -- | -99.99% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 59,710.40% | -76.52% | -- | -99.99% | -103.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 899.83% | -111.45% | -91.49% | -145.95% | -947.26% |